Page last updated: 2024-08-25

7-hydroxystaurosporine and perifosine

7-hydroxystaurosporine has been researched along with perifosine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alley, MC; Dasmahapatra, GP; Didolkar, P; Ghosh, S; Roy, KK; Sausville, EA	1
Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M	1

Trials

1 trial(s) available for 7-hydroxystaurosporine and perifosine

Article	Year
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Treatment Outcome; Young Adult	2013

Article

Year

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Investigational new drugs, 2013, Volume: 31, Issue:5

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Treatment Outcome; Young Adult

2013

Other Studies

1 other study(ies) available for 7-hydroxystaurosporine and perifosine

Article	Year
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Immunoblotting; Lung Neoplasms; Male; Phosphorylcholine; Prostatic Neoplasms; Signal Transduction; Staurosporine; Time Factors	2004

Article

Year

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15

Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Immunoblotting; Lung Neoplasms; Male; Phosphorylcholine; Prostatic Neoplasms; Signal Transduction; Staurosporine; Time Factors

2004